GlassScriptPhysician profile
Michelle Lorraine Mcqueen
NPI 1922381466
$1,688.13
in general payments reported to CMS, 2019-2025
25 companies · $208 in 2025
The $208 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $791 · 2022: $518 · 2023: $13.66 · 2024: $157 · 2025: $208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $379.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $378.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $317.69 | 2024-2025 | |
| Amgen INC. | $201.72 | 2021-2022 | |
| Lilly USA, LLC | $146.94 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.21 | 2021-2022 | |
| Novo Nordisk INC | $92.67 | 2021-2022 | |
| Glaxosmithkline, LLC. | $90.43 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $81.08 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $70.46 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $68.96 | 2021 | |
| Pfizer INC. | $54.66 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $51.37 | 2021-2022 | |
| Revance Therapeutics, INC. | $47.36 | 2024 | Daxxify |
| Avanir Pharmaceuticals, INC. | $44.05 | 2022 | |
| Abbvie INC. | $41.00 | 2021-2023 | |
| Biohaven Pharmaceuticals, INC. | $40.46 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $37.08 | 2021 | |
| Esperion Therapeutics, INC. | $32.85 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $27.09 | 2021 | |
| Neurelis, INC. | $24.76 | 2022 | |
| Urovant Sciences INC | $22.85 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $22.10 | 2022 | |
| Vanda Pharmaceuticals INC. | $20.77 | 2021 | |
| Astellas Pharma US INC | $16.39 | 2021 | |
| Impulse Dynamics (USA) INC. | $15.94 | 2022 | |
| Nestle Healthcare Nutrition INC. | $14.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Mcqueen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.